Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Pharmacoepidemiol Drug Saf ; 29(6): 708-715, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32173955

RESUMO

PURPOSE: Buprenorphine is an opioid partial agonist used to treat opioid use disorder. While several policy changes have attempted to increase buprenorphine availability, access remains well below optimal levels. This study characterized how buprenorphine utilization in the United States has changed over time and whether there are regional disparities in distribution of the medication. METHODS: The amount of buprenorphine distributed from 2007 to 2017 was obtained from the Drug Enforcement Administration's Automated Reports and Consolidated Ordering System. Data were expressed as the percent change and milligrams per person in each state. The formulations and cost for prescriptions covered by Medicaid (2008 to 2018) were also examined. RESULTS: Buprenorphine distributed to pharmacies increased about 7-fold (476.8 to 3179.9 kg) while the quantities distributed to hospitals grew 5-fold (18.6 to 97.6 kg) nationally from 2007 to 2017. Buprenorphine distribution per person was almost 20-fold higher in Vermont (40.4 mg/person) relative to South Dakota (2.1 mg/person). There was a strong association between the number of physicians authorized to prescribe buprenorphine and distribution per state (r[49] = +0.94, P < .0005). The buprenorphine/naloxone sublingual film (Suboxone) was the predominant formulation (92.6% of 0.31 million Medicaid prescriptions) in 2008 but accounted for less than three-fifth (57.3% of 6.56 million prescriptions) in 2018. CONCLUSIONS: Although buprenorphine availability has substantially increased over the last decade, distribution was very nonhomogeneous across the United States.


Assuntos
Analgésicos Opioides/uso terapêutico , Buprenorfina/uso terapêutico , Uso de Medicamentos/tendências , Disparidades em Assistência à Saúde/tendências , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Padrões de Prática Médica/tendências , Analgésicos Opioides/provisão & distribuição , Buprenorfina/provisão & distribuição , Combinação Buprenorfina e Naloxona/uso terapêutico , Composição de Medicamentos , Prescrições de Medicamentos , Humanos , Medicaid/tendências , Transtornos Relacionados ao Uso de Opioides/diagnóstico , Transtornos Relacionados ao Uso de Opioides/epidemiologia , Fatores de Tempo , Estados Unidos/epidemiologia
2.
Otolaryngol Head Neck Surg ; 168(3): 269-281, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-35671149

RESUMO

OBJECTIVE: Kaposi sarcoma (KS) of the larynx is a rare disease with few cases reported in the literature. This study aims to provide a comprehensive review of laryngeal KS, including patient characteristics, treatment, and clinical outcomes. DATA SOURCES: PubMed, CINAHL, SCOPUS, and Cochrane Library. REVIEW METHODS: A systematic review of the published English literature was conducted. An electronic search and bibliographic examination of articles pertaining to laryngeal KS were performed. Demographic data, tumor site, treatment strategies, follow-up, and outcome were analyzed. RESULTS: A total 77 cases from 50 articles were included in the review. The mean age was 47.6 years (range, 8-81). There was an 8.6:1 male:female ratio. The most common presenting symptoms were dyspnea (n = 35) and hoarseness (n = 25). Laryngeal KS arose most frequently in the supraglottic region (n = 16). Chemotherapy alone (n = 27) was the most common treatment modality in patients with AIDS-associated KS, and surgical excision alone (n = 7) was most common in patients with other subtypes of KS (eg, classic, transplant associated). Average follow-up was 20.4 months (range, 0.75-120). Most patients with AIDS-associated KS died of other causes (n = 25), but most patients with other subtypes of KS were alive with no evidence of disease at follow-up (n = 13). CONCLUSION: This review contains the largest pool of laryngeal KS cases to date. Long-term outcomes were generally unfavorable, often due to advanced HIV disease at the time of diagnosis.


Assuntos
Síndrome da Imunodeficiência Adquirida , Infecções por HIV , Laringe , Sarcoma de Kaposi , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Sarcoma de Kaposi/terapia , Sarcoma de Kaposi/tratamento farmacológico , Síndrome da Imunodeficiência Adquirida/complicações , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Infecções por HIV/complicações , Infecções por HIV/tratamento farmacológico , Laringe/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA